Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.

被引：0
|
作者：
Meng, Xiangrui
Yang, Xiuli
Hong, Yong-Gui
Zhang, Zhiye
Xia, Jin
Chen, Yunfang
Wu, Tao
Shan, Zheng-Zheng
Fan, Qingxia
Wang, Feng
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] First Affiliated Hosp, Nanyang Med Coll, Nanyang, Peoples R China
[3] Anyang Tumor Hosp, Anyang, Henan, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Med Oncol, Luoyang, Peoples R China
[5] Zhumadian Cent Hosp, Zhumadian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16035
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
    Wang, X.
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [42] A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.
    Wang, Feng
    Xia, Jin
    Meng, Xiangrui
    Ji, Yinghua
    Yang, Xiuli
    Hong, Yong-Gui
    Wang, Junsheng
    Cui, Donghai
    Luo, Zhiquan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial
    Negrier, Sylvie
    Rioux-Leclercq, Nathalie
    Ferlay, Celine
    Gross-Goupil, Marine
    Gravis, Gwenaelle
    Geoffrois, Lionel
    Chevreau, Christine
    Boyle, Helen
    Rolland, Frederic
    Blanc, Ellen
    Ravaud, Alain
    Dermeche, Slimane
    Flechon, Aude
    Albiges, Laurence
    Perol, David
    Escudier, Bernard
    EUROPEAN JOURNAL OF CANCER, 2020, 129 : 107 - 116
  • [44] Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1st-RT): A single-arm, open-label, phase 2 trial
    Han, Dan
    Li, Baosheng
    Huang, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.
    Wang, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II study
    Wang, Z.
    Qin, B.
    Ye, C.
    Wang, M.
    Yuan, L.
    Yao, H.
    Jiao, X.
    Liu, K.
    Sun, L.
    Dai, W.
    Ling, Y.
    Wu, Y.
    Chen, S.
    Zhang, Y.
    Shi, D.
    Duan, X.
    Zhong, X.
    He, X.
    Zhai, W.
    Zang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1433 - S1433
  • [47] Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
    Migden, Michael R.
    Khushalani, Nikhil I.
    Chang, Anne Lynn S.
    Lewis, Karl D.
    Schmults, Chrysalyne D.
    Hernandez-Aya, Leonel
    Meier, Friedegund
    Schadendorf, Dirk
    Guminski, Alexander
    Hauschild, Axel
    Wong, Deborah J.
    Daniels, Gregory A.
    Berking, Carola
    Jankovic, Vladimir
    Stankevich, Elizabeth
    Booth, Jocelyn
    Li, Siyu
    Weinreich, David M.
    Yancopoulos, George D.
    Lowy, Israel
    Fury, Matthew G.
    Rischin, Danny
    LANCET ONCOLOGY, 2020, 21 (02): : 294 - 305
  • [48] Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from an open-label, multicenter phase II trial (AK104-IIT-014).
    Qu, Wang
    Gao, Jing
    Zhang, Bo
    Liu, Yun
    Guo, Yijia
    Yang, Mudan
    Huang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 463 - 463
  • [49] First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
    Li, Tao
    Dong, Ying
    Wei, Yongzhong
    Wang, Shoufeng
    Liu, Yunxia
    Chen, Jia
    Xiong, Wenhua
    Lin, Nong
    Huang, Xin
    Liu, Meng
    Yan, Xiaobo
    Ye, Zhaoming
    Li, Binghao
    CLINICAL CANCER RESEARCH, 2024, 30 (19) : 4310 - 4317
  • [50] Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
    McDermott, David F.
    Lee, Jae-Lyun
    Bjarnason, Georg A.
    Larkin, James M. G.
    Gafanov, Rustem A.
    Kochenderfer, Mark D.
    Jensen, Niels Viggo
    Donskov, Frede
    Malik, Jahangeer
    Poprach, Alexandr
    Tykodi, Scott S.
    Alonso-Gordoa, Teresa
    Cho, Daniel C.
    Geertsen, Poul F.
    Climent Duran, Miguel Angel
    DiSimone, Christopher
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Schloss, Charles
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (09) : 1020 - 1028
12345